HLA-B*58:01 screening in Asia-Pacific is an ethical imperative – not just a cost question

Allopurinol remains the first-line treatment for gout; however, it carries a risk of severe cutaneous adverse reactions (SCARs), particularly among carriers of the HLA-B*58:01 allele. In the Asia-Pacific region, screening practices vary widely due to infrastructure gaps, cost concerns, and differing...

Full description

Bibliographic Details

Main Authors:	Ng, Wei Leik, Tse, Emily Tsui Yee, Oka, Prawira, Lim, Hooi Min, Koh, Sky Wei Chee, Ramli, Rizawati, Lau, Hung Chiun, Lam, Benjamin Chih Chiang, Goldsmith, Laurie J., Abdullah, Adina, Goh, Lay Hoon
Format:	Article
Language:	en
Published:	University of Edinburgh 2025
Online Access:	http://psasir.upm.edu.my/id/eprint/121388/1/121388.pdf http://psasir.upm.edu.my/id/eprint/121388/ https://jogh.org/2025/jogh-15-03037
Tags:	Add Tag No Tags, Be the first to tag this record!